Persistence to Onabotulinumtoxina versus Calcitonin Gene-related Peptide Monoclonal Antibodies (CGRP Mabs) Among Migraine Patients in a US Electronic Health Record Database

Amy Tung, PharmD, MS

AHSAM 2020 - Poster session
Published on September 3, 2020

2 minute listen

1 minute read

Key messages

  • This study evaluated early real-world persistence among 1976 adults with migraine treated with onabotulinumtoxinA or CGRP mAbs
  • In real-world practice, patients showed higher levels of persistence on onabotulinumtoxinA compared to CGRP mAbs for migraine
  • This was also true among patients with chronic migraine or episodic migraine
  • Podcast by Amy Tung, PharmD, MS

Key messages

  • This study evaluated early real-world persistence among 1976 adults with migraine treated with onabotulinumtoxinA or CGRP mAbs
  • In real-world practice, patients showed higher levels of persistence on onabotulinumtoxinA compared to CGRP mAbs for migraine
  • This was also true among patients with chronic migraine or episodic migraine

Podcast by Amy Tung, PharmD, MS

Amy Tung, PharmD, MS
Associate Director
Allergan plc
Irvine, California

Amy Tung, PharmD, MS, is an Associate Director in the Health Economics Outcomes Research group at Abbvie Inc (formerly Allergan Plc). She received her Doctorate of Pharmacy and Master in Science in Health Economics Outcomes Research from the University of Washington in Seattle, Washington. Amy currently resides in Huntington Beach, California.

Amy Tung, PharmD, MS: Allergan (Employment) (Salary)



Headache
Epidemiology


Scan to open on your mobile device